Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals. (encore1)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2012 by Kirby Institute.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Kirby Institute
ClinicalTrials.gov Identifier:
NCT01011413
First received: November 9, 2009
Last updated: November 6, 2012
Last verified: November 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: May 2014
  Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
No publications provided by Kirby Institute

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):